Premium Nahrungsergänzungsmittel | artgerecht

4-1BB Agonist: Mechanism of Action & Use in Oncology

A 4-1BB agonist is a therapeutic agent that activates the immune receptor 4-1BB, boosting the body's immune response against cancer cells. It is used in oncological immunotherapy.

Regular tips about health Regular tips about health Add as Preferred Source

Things worth knowing about "4-1BB Agonist"

A 4-1BB agonist is a therapeutic agent that activates the immune receptor 4-1BB, boosting the body's immune response against cancer cells. It is used in oncological immunotherapy.

What Is a 4-1BB Agonist?

A 4-1BB agonist is a biopharmaceutical agent that selectively activates the immune receptor 4-1BB (also known as CD137 or TNFRSF9). This receptor belongs to the tumor necrosis factor receptor (TNFR) superfamily and is primarily expressed on activated T lymphocytes (T cells) of the immune system. 4-1BB agonists are used in modern cancer immunotherapy (immuno-oncology) to enhance the body's natural defenses against tumor cells.

Mechanism of Action

The 4-1BB receptor is a costimulatory receptor, meaning it delivers an additional activation signal to T cells after they have recognized a tumor or pathogen. Without this secondary signal, T cells can become anergic (inactive) or undergo programmed cell death.

When a 4-1BB agonist binds to the receptor, it triggers a downstream signaling cascade with the following effects:

T cell proliferation: The number of active cytotoxic T cells (CD8+ T cells) capable of directly killing tumor cells is increased.
Enhanced T cell survival: Activation of 4-1BB inhibits apoptosis (programmed cell death) in T cells, prolonging their lifespan within the tumor microenvironment.
NK cell activation: In addition to T cells, natural killer (NK) cells are also activated, further contributing to anti-tumor immunity.
Memory cell formation: The treatment promotes the development of long-lived memory T cells that can respond more rapidly upon re-exposure to the tumor.

Medical Applications

4-1BB agonists are largely still under clinical development, but several have been investigated in early-phase clinical trials. Their primary areas of application include:

Solid tumors: e.g., melanoma, renal cell carcinoma, non-small cell lung cancer
Hematological malignancies: e.g., diffuse large B-cell lymphoma
Combination therapies: 4-1BB agonists are frequently developed in combination with other immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1) or bispecific antibodies to improve therapeutic efficacy.

Key Agents and Developments

The most notable 4-1BB agonists include:

Urelumab (BMS-663513): A fully human monoclonal antibody evaluated in early clinical trials, but associated with hepatotoxic side effects at higher doses.
Utomilumab (PF-05082566): Another monoclonal antibody with a more favorable safety profile, tested in combination with other therapies.
Bispecific antibodies: Newer agents combine 4-1BB activation with targeting of tumor-specific antigens (e.g., HER2, CD20) to achieve tumor-restricted activation and reduce systemic toxicity.

Side Effects and Safety

Activation of the immune system through 4-1BB agonists can lead to unwanted immune-mediated reactions. Key side effects include:

Hepatotoxicity: Liver toxicity, particularly observed with urelumab at high doses
Systemic inflammatory reactions: Fever, fatigue, cytokine release syndrome
Autoimmune reactions: Similar to other immune checkpoint inhibitors, inflammation in healthy tissues may occur

Research is therefore focused on next-generation antibodies designed to enable more selective activation within the tumor microenvironment, thereby minimizing systemic toxicity risks.

Significance in Modern Oncology

4-1BB agonists represent a promising approach in immuno-oncology. They complement existing strategies such as PD-1/PD-L1 inhibitors and CAR-T cell therapies by directly and durably enhancing effector T cell activity. Particularly in the context of bispecific antibodies and targeted combination therapies, they are attributed with high therapeutic potential.

References

Bartkowiak, T. & Curran, M. A. (2015). 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Frontiers in Oncology, 5, 117. https://doi.org/10.3389/fonc.2015.00117
Dharmadhikari, B. et al. (2022). CD137 (4-1BB) Agonists in Cancer Immunotherapy: From Bench to Bedside. Frontiers in Immunology, 13, 918960. https://doi.org/10.3389/fimmu.2022.918960
Chester, C., Ambulkar, S. & Kohrt, H. E. (2016). 4-1BB Agonism: Adding the Gas to Take Off Tumor Immunity. Cancer Immunology, Immunotherapy, 65, 1243–1248. https://doi.org/10.1007/s00262-016-1829-2

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category

Pionier in Lactoferrin & naturbasierten Nutraceuticals seit 2016

150k Empfänger: Werde Teil der Community!

Wissenschaftliche Beiträge, Ernährungs- & Gesundheitstipps, sowie Zugang zu exklusiven Angeboten. Melde Dich an & sichere Dir 10% Nachlass auf Deinen nächsten Einkauf.